Beyond LDL Cholesterol, a New Role for PCSK9

被引：50
|
作者：
Akram, Omar N. [1 ,2 ]
Bernier, Adeline [1 ,3 ]
Petrides, Francine [1 ]
Wong, Gida [1 ,4 ]
Lambert, Gilles [1 ,5 ]
机构：
[1] Heart Res Inst, Lipid Res Grp, Sydney, NSW, Australia
[2] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia
[3] Ecole Normale Super, F-75231 Paris, France
[4] Queen Elizabeth Hosp, Hong Kong, Hong Kong, Peoples R China
[5] Univ Nantes, Fac Med, Nantes, France
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2010年 / 30卷 / 07期
关键词：
atherosclerosis; lipoproteins; metabolism; DENSITY-LIPOPROTEIN-RECEPTOR; DOMINANT HYPERCHOLESTEROLEMIA; PLASMA-CHOLESTEROL; NONHUMAN-PRIMATES; MICE; PROPROTEIN-CONVERTASE-SUBTILISIN-KEXIN-TYPE-9;
D O I：
10.1161/ATVBAHA.110.209007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1279 / 1281
页数：3
相关论文
共 50 条
  • [1] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [2] Antibodies to PCSK9 A Superior Way to Lower LDL Cholesterol?
    Maxwell, Kara N.
    Breslow, Jan L.
    CIRCULATION RESEARCH, 2012, 111 (03) : 274 - 277
  • [3] Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
    Steinberg, Daniel
    Witztum, Joseph L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (24) : 9546 - 9547
  • [4] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Stein, Evan A.
    Mellis, Scott
    Yancopoulos, George D.
    Stahl, Neil
    Logan, Douglas
    Smith, William B.
    Lisbon, Eleanor
    Gutierrez, Maria
    Webb, Cheryle
    Wu, Richard
    Du, Yunling
    Kranz, Therese
    Gasparino, Evelyn
    Swergold, Gary D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (12) : 1108 - 1118
  • [5] PCSK9 and atherosclerosis: Looking beyond LDL regulation
    Ragusa, Rosetta
    Basta, Giuseppina
    Neglia, Danilo
    De Caterina, Raffaele
    Del Turco, Serena
    Caselli, Chiara
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (04)
  • [6] The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol
    Dutka, Mieczyslaw
    Zimmer, Karolina
    Cwiertnia, Michal
    Ilczak, Tomasz
    Bobinski, Rafal
    HEART FAILURE REVIEWS, 2024, 29 (05) : 917 - 937
  • [7] A review of PCSK9 inhibition and its effects beyond LDL receptors
    Dixon, Dave L.
    Trankle, Cory
    Buckley, Leo
    Parod, Eric
    Carbone, Salvatore
    Van Tassell, Benjamin W.
    Abbate, Antonio
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (05) : 1073 - 1080
  • [8] Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
    van der Tuin, Sam J. L.
    Kuhnast, Susan
    Berbee, Jimmy F. P.
    Verschuren, Lars
    Pieterman, Elsbet J.
    Havekes, Louis M.
    van der Hoorn, Jose W. A.
    Rensen, Patrick C. N.
    Jukema, J. Wouter
    Princen, Hans M. G.
    van Dijk, Ko Willems
    Wang, Yanan
    JOURNAL OF LIPID RESEARCH, 2015, 56 (11) : 2085 - 2093
  • [9] Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
    Ghosh, Moumita
    Gaelman, Cecilia
    Rudling, Mats
    Angelin, Bo
    JOURNAL OF LIPID RESEARCH, 2015, 56 (02) : 463 - 469
  • [10] Differential cholesterol uptake in liver cells: A role for PCSK9
    Luquero, Aureli
    Vilahur, Gemma
    Casani, Laura
    Badimon, Lina
    Borrell-Pages, Maria
    FASEB JOURNAL, 2022, 36 (05)
12345